125 related articles for article (PubMed ID: 37865228)
1. Detection of internal mammary chain infiltration in breast cancer patients by [
Garcia JR; Kauak M; Compte A; Bassa P; Llinares E; Valls E; Riera E
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2024; 43(2):73-78. PubMed ID: 37865228
[TBL] [Abstract][Full Text] [Related]
2. Impact of
Kirchner J; Martin O; Umutlu L; Herrmann K; Bittner AK; Hoffmann O; Mohrmann S; Gauler T; Theurer S; Antke C; Esposito I; Kinner S; Schaarschmidt BM; Kowall B; Lütke-Brintrup D; Stang A; Becker AS; Antoch G; Buchbender C
Eur J Radiol; 2020 Jul; 128():108975. PubMed ID: 32371185
[TBL] [Abstract][Full Text] [Related]
3. Local and whole-body staging in patients with primary breast cancer: a comparison of one-step to two-step staging utilizing
Kirchner J; Grueneisen J; Martin O; Oehmigen M; Quick HH; Bittner AK; Hoffmann O; Ingenwerth M; Catalano OA; Heusch P; Buchbender C; Forsting M; Antoch G; Herrmann K; Umutlu L
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2328-2337. PubMed ID: 30056547
[TBL] [Abstract][Full Text] [Related]
4. Comparison of nodal staging between CT, MRI, and [
Morawitz J; Bruckmann NM; Dietzel F; Ullrich T; Bittner AK; Hoffmann O; Ruckhäberle E; Mohrmann S; Häberle L; Ingenwerth M; Abrar DB; Sawicki LM; Breuckmann K; Fendler WP; Herrmann K; Buchbender C; Antoch G; Umutlu L; Kirchner J
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):992-1001. PubMed ID: 34476552
[TBL] [Abstract][Full Text] [Related]
5. Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer.
Cermik TF; Mavi A; Basu S; Alavi A
Eur J Nucl Med Mol Imaging; 2008 Mar; 35(3):475-83. PubMed ID: 17957366
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous whole-body ¹⁸F-FDG PET-MRI in primary staging of breast cancer: a pilot study.
Taneja S; Jena A; Goel R; Sarin R; Kaul S
Eur J Radiol; 2014 Dec; 83(12):2231-2239. PubMed ID: 25282709
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer staging in a single session: whole-body PET/CT mammography.
Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
[TBL] [Abstract][Full Text] [Related]
8. What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer?
Botsikas D; Bagetakos I; Picarra M; Da Cunha Afonso Barisits AC; Boudabbous S; Montet X; Lam GT; Mainta I; Kalovidouri A; Becker M
Eur Radiol; 2019 Apr; 29(4):1787-1798. PubMed ID: 30267154
[TBL] [Abstract][Full Text] [Related]
9. Additional value of F-18 FDG PET/CT for initial staging in breast cancer with clinically negative axillary nodes.
Jeong YJ; Kang DY; Yoon HJ; Son HJ
Breast Cancer Res Treat; 2014 May; 145(1):137-42. PubMed ID: 24682676
[TBL] [Abstract][Full Text] [Related]
10. PET/CT in breast cancer staging is useful for evaluation of axillary lymph node and distant metastases.
Davidson T; Shehade N; Nissan E; Sklair-Levy M; Ben-Haim S; Barshack I; Zippel D; Halevy A; Chikman B
Surg Oncol; 2021 Sep; 38():101567. PubMed ID: 33866190
[TBL] [Abstract][Full Text] [Related]
11. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
[TBL] [Abstract][Full Text] [Related]
12.
Ulaner GA; Castillo R; Wills J; Gönen M; Goldman DA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1420-1427. PubMed ID: 28456837
[TBL] [Abstract][Full Text] [Related]
13. Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.
Riegger C; Herrmann J; Nagarajah J; Hecktor J; Kuemmel S; Otterbach F; Hahn S; Bockisch A; Lauenstein T; Antoch G; Heusner TA
Eur J Nucl Med Mol Imaging; 2012 May; 39(5):852-63. PubMed ID: 22392069
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.
Melsaether AN; Raad RA; Pujara AC; Ponzo FD; Pysarenko KM; Jhaveri K; Babb JS; Sigmund EE; Kim SG; Moy LA
Radiology; 2016 Oct; 281(1):193-202. PubMed ID: 27023002
[TBL] [Abstract][Full Text] [Related]
15. A Role of PET/MR in Breast Cancer?
Bruckmann NM; Morawitz J; Fendler WP; Ruckhäberle E; Bittner AK; Giesel FL; Herrmann K; Antoch G; Umutlu L; Kirchner J
Semin Nucl Med; 2022 Sep; 52(5):611-618. PubMed ID: 35260243
[TBL] [Abstract][Full Text] [Related]
16. Breast imaging. Preoperative breast cancer staging: comparison of USPIO-enhanced MR imaging and 18F-fluorodeoxyglucose (FDC) positron emission tomography (PET) imaging for axillary lymph node staging--initial findings.
Stadnik TW; Everaert H; Makkat S; Sacré R; Lamote J; Bourgain C
Eur Radiol; 2006 Oct; 16(10):2153-60. PubMed ID: 16670863
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of 18F-FDG PET/CT in low 18F-FDG-avidity breast cancer subtypes: comparison with breast US and MRI.
Park HL; Yoo IR; O JH; Kim H; Kim SH; Kang BJ
Nucl Med Commun; 2018 Jan; 39(1):35-43. PubMed ID: 28984814
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET for axillary lymph node staging in primary breast cancer.
Crippa F; Gerali A; Alessi A; Agresti R; Bombardieri E
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S97-102. PubMed ID: 15133635
[TBL] [Abstract][Full Text] [Related]
19. Prone Versus Supine Breast FDG-PET/CT for Assessing Locoregional Disease Distribution in Locally Advanced Breast Cancer.
Abramson RG; Lambert KF; Jones-Jackson LB; Arlinghaus LR; Williams J; Abramson VG; Chakravarthy AB; Yankeelov TE
Acad Radiol; 2015 Jul; 22(7):853-9. PubMed ID: 25865435
[TBL] [Abstract][Full Text] [Related]
20. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer.
Aukema TS; Straver ME; Peeters MJ; Russell NS; Gilhuijs KG; Vogel WV; Rutgers EJ; Olmos RA
Eur J Cancer; 2010 Dec; 46(18):3205-10. PubMed ID: 20719497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
